COVID-19 Infection

Not yet recruiting

• Conditions: COVID-19; Renal Transplant Infection
• Interventions: Other: Treatment plan

• Registration Number: NCT05926076
• Lead Sponsor: Tianjin First Central Hospital

Brief Summary

Post-transplant patients with COVID-19 infection who attended Shenzhen No. 3 Hospital from December 2022 to February 2023, and enrolled the general population with COVID-19 infection who were hospitalized during the same period, matched by age and gender.

Detailed Description

Data collection：Age, BMI, underlying comorbidities and other basic information were collected retrospectively from the two groups. The medical records were used to collect information about the patients' new coronavirus infection, such as the time of onset of symptoms, time of diagnosis, time of conversion and common symptoms such as fever, cough, nasal congestion and runny nose, muscle aches and pains.To compare the differences of the diagnosis and treatment of KTRs and the general population infected with Omicron

Study Timeline

• Status Verified: 2023-06
• Study First Submitted: 2023-06-24
• Study First Submitted QC: 2023-06-27
• Last Update Submitted: 2023-06-27
• Study First Posted: 2023-07-03
• Last Update Posted: 2023-07-03
• Study Start: 2023-07-25
• Primary Completion: 2023-07-30
• Study Completion: 2023-07-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 610

Inclusion Criteria

Confirmed novel coronavirus infection between December 2022 to February 2023,

Exclusion Criteria

Age less than 18; failure of the transplanted kidney before the new coronavirus infection; exclusion of oral immunosuppressed and other types of organ transplant recipients from the non-renal transplant population

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Non-Kidney Transplant Recipients Group（NKTR）	Treatment plan	-
Kidney Transplant Recipients Group (KTR)	Treatment plan	-

Primary Outcome Measures

Name	Time	Method
ICU admission or death	through study completion, an average of 1 month	patients have ICU admission or death

Trial Locations

Locations (1)

yingxin Fu; 🇨🇳 Shenzhen, Guangdong, China